Chembio Diagnostics (NASDAQ:CEMI) released its quarterly earnings data on Thursday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.10), Fidelity Earnings reports. Chembio Diagnostics had a negative return on equity of 26.91% and a negative net margin of 16.54%. The business had revenue of $9.38 million during the quarter.
Shares of Chembio Diagnostics stock traded down $0.47 on Friday, hitting $6.78. The company’s stock had a trading volume of 727,980 shares, compared to its average volume of 126,979. Chembio Diagnostics has a 52-week low of $6.44 and a 52-week high of $11.55. The company has a quick ratio of 2.58, a current ratio of 3.53 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $103.83 million, a PE ratio of -13.04 and a beta of 1.46.
In other Chembio Diagnostics news, insider Robert Passas acquired 15,000 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The shares were acquired at an average cost of $6.75 per share, for a total transaction of $101,250.00. Following the transaction, the insider now directly owns 15,000 shares of the company’s stock, valued at $101,250. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.65% of the stock is owned by insiders.
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Featured Article: Why is Cost of Capital Important?
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.